Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Unaudited consolidated results for the quarter (Q3) and nine months ended December 31, 2014 (FY15).
Business Overview: An integrated global pharmaceutical company operating through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products segments.
Key Financial Metrics
Quarter Ended December 31, 2014 (Q3 FY15)
| Metric | Value (INR Billion) | Value (USD Million) | % of Revenue |
|---|---|---|---|
| Revenues | 38.4 | 610 | 100% |
| Gross Profit | 22.4 | 355 | 58.2% |
| EBITDA | 10.5 | 167 | 27.3% |
| Profit After Tax | 5.7 | 91 | 15.0% |
| Diluted EPS | 33.61 | 0.53 | - |
| Capital Expenditure | 2.65 | - | - |
Nine Months Ended December 31, 2014 (9M FY15)
- Revenues: INR 109.5 billion (YoY growth of 12%).
- EBITDA: INR 28.1 billion (26% of revenues).
Liquidity and Balance Sheet (As of Dec 31, 2014)
- Cash and Cash Equivalents: INR 28.7 billion (USD 456 million).
- Loans and Borrowings: INR 39.7 billion (USD 629 million).
- Trade Receivables: INR 40.2 billion (USD 638 million).
- Equity: INR 105.1 billion (USD 1,667 million).
Material Changes vs. Prior Period
- Revenue Growth: Q3 revenues grew 9% YoY to INR 38.4 billion. Global Generics grew 8% (INR 31.7 billion), while PSAI grew 21% (INR 6.1 billion).
- Margin Compression: Gross profit margin declined 230 basis points to 58.2% (from 60.5% in Q3 FY14), primarily due to unfavorable currency impacts.
- Expense Increases:
- R&D expenses rose 45% YoY to INR 4.3 billion (11.2% of revenue) due to planned scale-up in development.
- SG&A expenses increased 12% YoY to INR 11.2 billion (29.0% of revenue), driven by annual increments and marketing spend.
- Profitability: Profit after tax declined 7% YoY to INR 5.7 billion. Operating profit margin decreased to 18.8% from 24.5%.
- Impairment: An impairment charge of INR 534 million was recorded on intangible assets related to product/customer contracts.
- Finance Income: Net finance income surged to INR 1.0 billion (from INR 15 million) due to forex benefits and profit on sales of investments.
Guidance, Outlook, and Management Commentary
- Strategic Acquisitions: Completed the acquisition of the Habitrol franchise (nicotine replacement therapy) from Novartis for USD 80 million; marketing began in the U.S.
- Product Pipeline: Launched 13 new generic products, filed 18 new product registrations, and 14 DMFs globally during the quarter.
- Regional Performance:
- North America: Revenue grew 4% YoY; sequential growth of 17% in constant currency driven by limited competition launches.
- Emerging Markets: Revenue grew 16% YoY. Excluding Russia, growth was 51% driven by Venezuela. Russia revenue declined 9% due to Rouble depreciation (27% growth in constant currency).
- India: Revenue grew 11% YoY.
- Risks and Contingencies: Forward-looking statements are subject to risks including global economic conditions, market acceptance of products, and currency fluctuations. The filing notes that actual results may differ materially from projections.
Investor Verification Checklist
- Verify the impact of currency fluctuations on reported margins and regional revenue growth, particularly in Russia and Emerging Markets.
- Confirm the integration progress and revenue contribution of the newly acquired Habitrol franchise.
- Monitor the status of the 68 pending ANDAs with the USFDA, specifically the 13 with "First To File" status.
- Assess the sustainability of the 45% increase in R&D spend and its impact on future product launches.
- Review the details of the INR 534 million impairment charge to understand the specific assets affected.